Literature DB >> 20541699

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Raymond J Andersen1, Nasrin R Mawji, Jun Wang, Gang Wang, Simon Haile, Jae-Kyung Myung, Kate Watt, Teresa Tam, Yu Chi Yang, Carmen A Bañuelos, David E Williams, Iain J McEwan, Yuzhou Wang, Marianne D Sadar.   

Abstract

Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity. Here we identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors. EPI-001 interacted with the AF-1 region, inhibited protein-protein interactions with AR, and reduced AR interaction with androgen-response elements on target genes. Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541699     DOI: 10.1016/j.ccr.2010.04.027

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  212 in total

1.  The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.

Authors:  Hongbo Wang; Ming Jiang; Hongmei Cui; Mengqian Chen; Ralph Buttyan; Simon W Hayward; Tsonwin Hai; Zhengxin Wang; Chunhong Yan
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

Review 2.  Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation.

Authors:  Raj Kumar; Iain J McEwan
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

3.  Prostate cancer: A new tARget.

Authors:  Mhairi Skinner
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

Review 4.  Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.

Authors:  Marianne D Sadar
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

Review 5.  Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

Authors:  Cameron M Armstrong; Allen C Gao
Journal:  Am J Clin Exp Urol       Date:  2015-08-08

Review 6.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

Review 7.  Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

Authors:  Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina
Journal:  Endocr Relat Cancer       Date:  2015-02-26       Impact factor: 5.678

Review 8.  Novel therapies for the treatment of advanced prostate cancer.

Authors:  J M Clarke; A J Armstrong
Journal:  Curr Treat Options Oncol       Date:  2013-03

Review 9.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

10.  An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.

Authors:  Yusuke Imamura; Amy H Tien; Jinhe Pan; Jacky K Leung; Carmen A Banuelos; Kunzhong Jian; Jun Wang; Nasrin R Mawji; Javier Garcia Fernandez; Kuo-Shyan Lin; Raymond J Andersen; Marianne D Sadar
Journal:  JCI Insight       Date:  2016-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.